MELBOURNE, Australia, Nov. 3, 2015 (GLOBE NEWSWIRE) -- Gordagen Pharmaceuticals, a privately held Australian company commercializing tocotrienol-based nutraceuticals and pharmaceuticals, has appointed Nutritional Products International, Inc. (NPI) as its exclusive US marketing and distribution partner for its Heart Health nutraceutical product.
nE1-Heart™ is an evidence-based nutraceutical for the maintenance of a healthy heart and is planned for release in the US during the first half of 2016, bringing forward previously forecasted revenues for the company. The US represents one of the largest nutraceutical markets in the world.
"This is a major step forward in our entry into the US market, and partnerships such as this are a key component of our overall growth strategy. Together with NPI, we are planning to launch our Heart Health product earlier than originally anticipated. As our first product to be launched into the US, which is a significant nutraceutical market, we feel this partnership will provide us with the greatest ability to capture solid market share," said Dr Glenn Tong, CEO and Managing Director of Gordagen.
NPI was selected following an extensive search, due to their significant knowledge and capability, strong industry and buyer relationships, as well as their understanding and focus on health/wellness and sports markets. As part of the agreement, NPI will handle all marketing and multi-channel distribution relationships for this product.
"We are delighted to enter this partnership with NPI, as their network of multi-channel distribution, including online retailers through to traditional bricks and mortar, affords Gordagen access to the infrastructure and workforce necessary to conduct a successful product launch in the US," commented Dr Rocco Iannello, Gordagen's Director of Business Development.
Gordagen's Heart Health nutraceutical is a specially-formulated tablet based on annatto-derived tocotrienols and utilizes Gordagen's proprietary and patent-pending MELT3™ technology platform. Gordagen sees a dual potential for its Heart Health product – helping to maintain a healthy heart and also in combination with a healthy diet and active lifestyle, in the fight against cardiovascular disease risk factors.
Gordagen recently announced the engagement of Natural Alternatives International, Inc. as the Company's cGMP manufacturing partner. With the appointment of NAI and NPI, Gordagen's plans to make a strong entry into the US evidence-based nutraceuticals market is rapidly taking shape.
"We are excited to be partnering with Gordagen to take their innovative heart health nutraceutical to the US market. This will be Gordagen's first product in the US and we are very proud that they have chosen NPI as their US strategic partner for such an important market," said Mitch Gould, CEO of NPI.
Gordagen is currently developing tocotrienol-based nutraceuticals backed by clinical research in accord with Good Clinical Practice principles, for the muscle soreness, exercise endurance and heart health markets. It has a diverse prescription pharmaceutical portfolio, covering core indications of cardiovascular disease, diabetes and hypertension, among others. The Company's proprietary and patent-pending MELT3™ melt-then-swallow technology is combined with a unique formulation of tocotrienols.
About Gordagen Pharmaceuticals Pty Ltd
Gordagen Pharmaceuticals is a privately-held Australian company developing and commercializing nutraceuticals and prescription medicines based on tocotrienols, found in vitamin E. The Company has developed a novel approach to delivering highly potent tocotrienols to target tissues using its proprietary and patent-pending "melt-then-swallow" delivery technology (MELT3TM). The Company is focusing on tocotrienols with wide therapeutic potential, initially targeting heart health, muscle soreness and exercise endurance.
About Nutritional Products International, Inc. (NPI)
NPI (Nutritional Products International), one of the world's leading nutraceutical companies, provides sales and marketing solutions for products worldwide, enabling them to be successful with consumers in the U.S. The company maintains strong relationships with key buyers all over the country, providing foreign brands with a fast track to the world's most important market. Its website is http://www.nutricompany.com.
CONTACT: For Further Enquiries: Company Dr Glenn Tong Managing Director & CEO Tel: +61 (0) 412 193 350 Australia Paris Brooke Bt Novo Pty Ltd Tel: +61 (0) 407 715 574 United States David Burke The Ruth Group O: 646.536.7009 C: 917-618-2651